Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening

NCT ID: NCT01783288

Last Updated: 2026-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine whether patients meet criteria for Postural Tachycardia Syndrome (or not) and have reduced blood volume (or not). Both of these are important screening elements to Aim 3 of a National Institutes of Health Grant. The purposes of Aim 3 are to determine 1. whether a high dietary sodium level appropriately expands plasma volume in Postural Orthostatic Tachycardia, 2. whether plasma renin activity and aldosterone are modified appropriately by changes in dietary sodium in Postural Tachycardia Syndrome and 3. whether patients with Postural Tachycardia Syndrome have improvements in their orthostatic tachycardia and symptoms as a result of a high dietary sodium level.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The protocol consists of a screening visit and evaluation of their autonomic nervous system status. The following activities are part of this study. Subjects may stay for 2 nights and 3 study days.

Day 0 Participants will be admitted to the Clinical Research Center, their medical history, physical exam, routine lab work (hemoglobin/hematocrit \& CMP) and a serum pregnancy test will be done during that first day. They will also be asked to fill out a health questionnaire. Later that day they will be evaluated to determine the extent of fatigue, depression and anxiety ratings, autonomic symptoms and quality of life, with the use of questionnaires.

Subjects may be asked to stop taking some medications for up to 7 days; it will be decided on an individual basis and after considering each medication and its effect to the autonomic nervous system. If subjects are asked to discontinue the medication, they will ask them to keep a diary of symptoms and to contact the PI or staff by phone if any new symptom appears. If necessary, medications will be restarted.

Testing day 1:

In the morning during the posture test, 5 teaspoons of blood will be drawn while subject is lying down, and after sitting and or standing for 30 minutes to measure substances produced by the body in response to inflammation and oxidative stress and to determine hormones that regulate the blood pressure. Blood pressure and heart rate will be measured in these different positions. A total of 10 tablespoons will be drawn.

In the afternoon, more tests will be performed designed to determine how well the autonomic nervous system is working in regulating blood pressure and heart rate. Autonomic function test will be performed to see how the involuntary nervous system is working. For these tests, heart rate will be recorded using a continuous electrocardiographic trace, blood pressure using a cuff around one arm and/or finger and heart's pumping capacity (cardiac output) will be measured by analyzing the shift of fluids in the body (body impedance) and/or by analyzing the air that is breathe.

Participants will be tilted up on a tilt table for 10 minutes while recording their heart rate and blood pressure. The autonomic function tests include asking the participants to breathe deeply for two minutes and breathing rapidly for 30 seconds, maintaining a handgrip for 3 minutes, blowing against pressure for 15 seconds and placing one hand in ice water for 1 minute. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working.

Testing day 2:

In the morning, total blood volume will be measured by using iodinated I-131 tagged human serum albumin, a material with a very small amount of radioactive substance. The test involves drawing a blood sample before the I-131 is given, then giving the I-131 through a catheter in one vein, waiting 12 minutes before the second blood sample is drawn to check its concentration. Blood samples will also be drawn while subjects are lying down to measure for hormones, which control blood pressure and heart rate. Blood will drawn at several points during the study. The total amount of blood drawn during this study is approximately 3 teaspoons.

In the afternoon, exercise capacity test with estimation of maximal oxygen consumption (VO2 max) will be done. This test will be conducted on a stationary bicycle and the resistance will be gradually increased while the expired air is measured during exhaustive physical work. The test will last approximately 30 minutes. A mouthpiece with a one way re-breathing valve attached to a breathing tube will be used to collect air samples during the exercise test. Essentially, subjects will breathe room air through a mouthpiece, and then expire the air into a tube that connects to a machine (metabolic cart). This machine analyzes carbon dioxide and oxygen content, which allows us to calculate the amount of oxygen they are using under resting and exercise conditions.

The workload will be gradually increased on the bike by increasing the resistance. As the workload increases, oxygen consumption also increases. Throughout the test period exhaled air will be collected. When subjects can no longer continue, the test will be stopped. Blood pressure will be measured at the end of each resistance-stage. Heart rate data will be recorded continuously.

Before and after completing the exercise test, subjects will be required to complete a "warm-up" and "cool-down" session including stretching exercises.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postural Tachycardia Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All participants

All participants will be administered all procedures as described previously.

Interventions:

Autonomic Function Testing, Posture Study ,Measurement of Total Blood Volume ,Exercise Capacity Test

Group Type OTHER

Autonomic Function Testing

Intervention Type OTHER

heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.

Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed.

Posture Study

Intervention Type OTHER

Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured \& collected in the supine (lying) and upright position for each participant.

Measurement of Total Blood Volume

Intervention Type PROCEDURE

Total blood volume is measured by using iodinated I-131 tagged human serum albumin.

Exercise Capacity Test

Intervention Type OTHER

Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autonomic Function Testing

heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.

Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed.

Intervention Type OTHER

Posture Study

Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured \& collected in the supine (lying) and upright position for each participant.

Intervention Type OTHER

Measurement of Total Blood Volume

Total blood volume is measured by using iodinated I-131 tagged human serum albumin.

Intervention Type PROCEDURE

Exercise Capacity Test

Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Supine & standing blood pressure, heart rate & blood draws. blood sample at baseline and at 12 minutes I-131 is administered. Masimal Oxygen Consumption Test

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18-50 years old
* Patients with suspected POTS and healthy volunteers
* Sedentary healthy subjects of similar age and gender than patients will also be recruited.
* Only female participants are eligible.
* Able and willing to provide informed consent

Exclusion Criteria

* Smokers
* Overt cause for postural tachycardia, i.e., acute dehydration
* Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or prior testing
* Highly trained athletes
* Subjects with somatization or severe anxiety symptoms will be excluded
* Pregnant (positive pregnancy test) or breastfeeding
* Hypertension defined as supine resting BP\>145/95 mmHg off medications or needing antihypertensive medication
* Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
* Unable to give informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institutes of Health (NIH)

NIH

Sponsor Role collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role collaborator

Vanderbilt University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alfredo Gamboa

Research Associate Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alfredo J Gamboa, MD

Role: PRINCIPAL_INVESTIGATOR

Vanderbilt University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01HL102387

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB 121817

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.